Clinical Trial Update: Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for pazopanib/doxorubicin in relapsed platinum-sensitive or resistant ovarian, fallopian tube, or primary peritoneal adenocarcinoma (Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Carcinoma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Pazopanib (Pazopanib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-05-21